Skip to main content
SpringerLink
Log in

Consider specific co-morbidities and disease aetiology when treating hypertension in patients with chronic kidney disease

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Maintaining blood pressure control and reducing proteinuria in hypertensive patients with chronic kidney disease is crucial to prevent the progression of kidney disease and the development or worsening of cardiovascular disease. Pharmacological treatment recommendations vary depending on the specific aetiology of disease, as well as patient characteristics. The majority of patients will require multi-drug therapy in order to achieve blood pressure goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Talreja H, Ruzicka M, McCormick BB. Pharmacologic treatment of hypertension in patients with chronic kidney disease. Am J Cardiovasc Drugs. 2013;13(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  2. Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55(3):441–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Strazzullo P, Galletti F, Barba G. Altered renal handling of sodium in human hypertension: short review of the evidence. Hypertension. 2003;41(5):1000–5.

    Article  CAS  PubMed  Google Scholar 

  4. Weidmann P, Maxwell MH, Lupu AN, et al. Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med. 1971;285(14):757–62.

    Article  CAS  PubMed  Google Scholar 

  5. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8.

    Article  PubMed  Google Scholar 

  6. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64(5):1772–9.

    Article  PubMed  Google Scholar 

  7. Boudville N, Ward S, Benaroia M, et al. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens. 2005;18(10):1300–5.

    Article  CAS  PubMed  Google Scholar 

  8. Rabi DM, Daskalopoulou SS, Padwal RS, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol. 2011;27(4):415–33 e1-2.

    Google Scholar 

  9. Kidney Disease Outcomes Quality Initiative (K/DOQI). KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):1–290.

    Google Scholar 

  10. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6):387–95.

    Article  CAS  PubMed  Google Scholar 

  11. Acchiardo SR, Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in renal impairment. Am Heart J. 1983;106(1 Pt 2):237–44.

    Article  CAS  PubMed  Google Scholar 

  12. Dargie HJ, Allison ME, Kennedy AC, et al. Efficacy of metolazone in patients with renal edema. Clin Nephrol. 1974;2(4):157–60.

    CAS  PubMed  Google Scholar 

  13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857–63.

    Article  Google Scholar 

  14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.

    Article  Google Scholar 

  15. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.

    Article  CAS  PubMed  Google Scholar 

  16. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.

    Article  CAS  PubMed  Google Scholar 

  17. Hemodialysis Adequacy Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48(Suppl 1):S2–90.

    Google Scholar 

  18. Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438–44.

    Article  CAS  PubMed  Google Scholar 

  19. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–28.

    Article  CAS  PubMed  Google Scholar 

  20. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45.

    Article  CAS  PubMed  Google Scholar 

  21. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2116–23.

    CAS  PubMed  Google Scholar 

  22. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.

    Article  CAS  PubMed  Google Scholar 

  23. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.

    Article  CAS  PubMed  Google Scholar 

  24. Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens. 1996;9(7):633–43.

    Article  CAS  PubMed  Google Scholar 

  25. Hermida RC, Ayala DE, Mojon A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011;22(12):2313–21.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from the American Journal of Cardiovascular Drugs 2013;13(3):177–88 [1]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Cite this article

    Adis Medical Writers. Consider specific co-morbidities and disease aetiology when treating hypertension in patients with chronic kidney disease. Drugs Ther Perspect 30, 60–64 (2014). https://doi.org/10.1007/s40267-013-0091-3

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-013-0091-3

    Keywords

    Search

    Navigation